BACKGROUND: Many ovarian cancer patients will after treatment of the recurrence with cisplatin based therapy enter phase I or II studies with new drugs. Lately, some new agents have shown activity. MATERIALS AND METHODS: The review is based on phase II studies mainly and focuses on paclitaxel (taxol). RESULTS: A Canadian/European study of high (175 mg/m2) versus low dose (135 mg/m2), and short (3 hours) versus long (24 hours) infusion confirms the reported activity of paclitaxel in previously treated patients. The preliminary overall response rate in 286 evaluable patients is 18.5%. A dose effect exists regarding neuropathy and neutropenia, and a longer infusion duration results in a higher frequency of grade 4 neutropenia. In a phase III study comparing cisplatin 75 mg/m2 plus cyclophosphamide (750 mg/m2) or plus paclitaxel 135 mg/m2 over 24 hours, the paclitaxel-based combination gave a superior response rate (54% versus 33%) and statistically significant longer progression-free interval. The semisynthetic docetaxel (taxotere) gives an overall response rate of 32% (95% confidence interval 23%-43%). Skin toxicity and edema are dose-limiting factors. Gemcitabine has also shown activity in platinum-resistant patients with an overall response rate of 23% (95% CI 10%-40%). CONCLUSIONS: The role of new drugs in first-line therapy remains to be seen. Further development of experimental work for screening and evaluation of new agents is needed.
BACKGROUND: Many ovarian cancerpatients will after treatment of the recurrence with cisplatin based therapy enter phase I or II studies with new drugs. Lately, some new agents have shown activity. MATERIALS AND METHODS: The review is based on phase II studies mainly and focuses on paclitaxel (taxol). RESULTS: A Canadian/European study of high (175 mg/m2) versus low dose (135 mg/m2), and short (3 hours) versus long (24 hours) infusion confirms the reported activity of paclitaxel in previously treated patients. The preliminary overall response rate in 286 evaluable patients is 18.5%. A dose effect exists regarding neuropathy and neutropenia, and a longer infusion duration results in a higher frequency of grade 4 neutropenia. In a phase III study comparing cisplatin 75 mg/m2 plus cyclophosphamide (750 mg/m2) or plus paclitaxel 135 mg/m2 over 24 hours, the paclitaxel-based combination gave a superior response rate (54% versus 33%) and statistically significant longer progression-free interval. The semisynthetic docetaxel (taxotere) gives an overall response rate of 32% (95% confidence interval 23%-43%). Skin toxicity and edema are dose-limiting factors. Gemcitabine has also shown activity in platinum-resistant patients with an overall response rate of 23% (95% CI 10%-40%). CONCLUSIONS: The role of new drugs in first-line therapy remains to be seen. Further development of experimental work for screening and evaluation of new agents is needed.
Authors: Patricia L Judson; Entidhar Al Sawah; Douglas C Marchion; Yin Xiong; Elona Bicaku; Nadim Bou Zgheib; Hye Sook Chon; Xiaomang B Stickles; Ardeshir Hakam; Robert M Wenham; Sachin M Apte; Jesus Gonzalez-Bosquet; Dung-Tsa Chen; Johnathan M Lancaster Journal: Int J Gynecol Cancer Date: 2012-07 Impact factor: 3.437
Authors: Douglas C Marchion; Hope M Cottrill; Yin Xiong; Ning Chen; Elona Bicaku; William J Fulp; Nisha Bansal; Hye Sook Chon; Xiaomang B Stickles; Siddharth G Kamath; Ardeshir Hakam; Lihua Li; Dan Su; Carolina Moreno; Patricia L Judson; Andrew Berchuck; Robert M Wenham; Sachin M Apte; Jesus Gonzalez-Bosquet; Gregory C Bloom; Steven A Eschrich; Said Sebti; Dung-Tsa Chen; Johnathan M Lancaster Journal: Clin Cancer Res Date: 2011-08-17 Impact factor: 12.531
Authors: Entidhar Al Sawah; Douglas C Marchion; Yin Xiong; Ingrid J Ramirez; Forough Abbasi; Bernadette M Boac; Stephen H Bush; Nadim Bou Zgheib; E Clair McClung; Beman R Khulpateea; Amy Berry; Ardeshir Hakam; Robert M Wenham; Johnathan M Lancaster; Patricia L Judson Journal: J Cancer Res Clin Oncol Date: 2014-08-28 Impact factor: 4.553
Authors: Nisha Bansal; Douglas C Marchion; Elona Bicaku; Yin Xiong; Ning Chen; Xiaomang B Stickles; Entidhar Al Sawah; Robert M Wenham; Sachin M Apte; Jesus Gonzalez-Bosquet; Patricia L Judson; Ardeshir Hakam; Johnathan M Lancaster Journal: J Gynecol Oncol Date: 2012-01-09 Impact factor: 4.401